Ralaniten

Ralaniten

Clinical data
Other names	EPI-002
Drug class	Nonsteroidal antiandrogen
Identifiers
IUPAC name (2R)-3-[4-[2-[4-[(2S)-3-Chloro-2-hydroxypropoxy]phenyl]propan-2-yl]phenoxy]propane-1,2-diol
CAS Number	1203490-23-6
PubChem CID	45107537
ChemSpider	58827834
UNII	WC830G6O4X
KEGG	D11184
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H27ClO5
Molar mass	394.89 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C1=CC=C(C=C1)OC[C@@H](CO)O)C2=CC=C(C=C2)OC[C@@H](CCl)O
InChI InChI=1S/C21H27ClO5/c1-21(2,15-3-7-19(8-4-15)26-13-17(24)11-22)16-5-9-20(10-6-16)27-14-18(25)12-23/h3-10,17-18,23-25H,11-14H2,1-2H3/t17-,18-/m1/s1 Key:HDTYUHNZRYZEEB-QZTJIDSGSA-N

Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. It is a derivative of bisphenol A and one of the four stereoisomers of EPI-001. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.

See also

• EPI-7386